IL148674A0 - Modulation of enos activity and therapeutic uses thereof - Google Patents

Modulation of enos activity and therapeutic uses thereof

Info

Publication number
IL148674A0
IL148674A0 IL14867400A IL14867400A IL148674A0 IL 148674 A0 IL148674 A0 IL 148674A0 IL 14867400 A IL14867400 A IL 14867400A IL 14867400 A IL14867400 A IL 14867400A IL 148674 A0 IL148674 A0 IL 148674A0
Authority
IL
Israel
Prior art keywords
modulation
therapeutic uses
enos activity
enos
activity
Prior art date
Application number
IL14867400A
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL148674A0 publication Critical patent/IL148674A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
IL14867400A 1999-11-02 2000-11-02 Modulation of enos activity and therapeutic uses thereof IL148674A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16313299P 1999-11-02 1999-11-02
PCT/US2000/030294 WO2001032695A2 (en) 1999-11-02 2000-11-02 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF

Publications (1)

Publication Number Publication Date
IL148674A0 true IL148674A0 (en) 2002-09-12

Family

ID=22588624

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14867400A IL148674A0 (en) 1999-11-02 2000-11-02 Modulation of enos activity and therapeutic uses thereof

Country Status (6)

Country Link
EP (1) EP1225910A2 (en)
JP (1) JP2003513105A (en)
AU (1) AU782158B2 (en)
CA (1) CA2385665A1 (en)
IL (1) IL148674A0 (en)
WO (1) WO2001032695A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007110847A (en) * 2004-08-20 2008-09-27 Де Джонс Хопкинс Юниверсити (US) METHODS FOR TREATING ANGIOGENESIS
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
ATE287271T1 (en) * 1996-11-01 2005-02-15 Ark Therapeutics Ltd USE OF VEGF FOR PRODUCING A MEDICATION FOR TREATING OR PREVENTING INTIMAL HYPERPLASIA AND ADMINISTRATION DEVICE
WO2000013702A2 (en) * 1998-09-09 2000-03-16 Scios Inc. Use of an angiogenic factor for the treatment of microvascular angiopathies
KR100634926B1 (en) * 1999-04-16 2006-10-17 제넨테크, 인크. Vascular endothelial cell growth factor variants and uses thereof
WO2000071713A1 (en) * 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor variants

Also Published As

Publication number Publication date
WO2001032695A3 (en) 2002-02-14
JP2003513105A (en) 2003-04-08
AU782158B2 (en) 2005-07-07
EP1225910A2 (en) 2002-07-31
WO2001032695A2 (en) 2001-05-10
CA2385665A1 (en) 2001-05-10
AU1756501A (en) 2001-05-14

Similar Documents

Publication Publication Date Title
IL144954A0 (en) Quinazolines and therapeutic use thereof
EP1227821A4 (en) Therapeutic compositions and methods of use thereof
PL349355A1 (en) Diaryl derivatives and their application as therapeutic agents
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
PL335555A1 (en) Novel compounds - substituted benzamides and therapeutic agent
AU5009200A (en) Novel beta-secretase and modulation of beta-secretase activity
AU6895900A (en) Methods of modulating matrix metalloproteinase activity and uses thereof
IL130171A0 (en) Therapeutic use of melatonin
GB9712761D0 (en) Quinolines and their therapeutic use
IL148674A0 (en) Modulation of enos activity and therapeutic uses thereof
IL131347A0 (en) Treatment of skin disorders
ZA986047B (en) 6-pyrrolidin-2-ylpyrindines their preparation and their therapeutic application
GB9908059D0 (en) Diagnosis and treatment of diseases
GB9903919D0 (en) Aminophenols and their therapeutic use
EP1194527A4 (en) Stress-responsive induction of a therapeutic agent and methods of use
GB9905307D0 (en) Therapy and use of compounds in therapy
GB9905315D0 (en) Therapy and use of compounds in therapy
AU2595201A (en) Antiviral therapeutic composition and treatment
GB9725044D0 (en) Microparticles and their therapeutic use
GB9926528D0 (en) Therapeutic use and formulation
PL342096A1 (en) Sunburning and therapeutic appliance
SI1121108T1 (en) Novel therapeutic use of compounds with beta-3-agonist activity
PL351313A1 (en) Transdermal therapeutic system comprising nictotine with addition of monoterenic ketones
GB9905300D0 (en) Therapy and use of agents in therapy
GB9704350D0 (en) Compounds and their therapeutic use